Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 7, 2011, Pages 993-999

  Hotta, Katsuyuki ^a   Kiura, Katsuyuki ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

elrotinib; non small cell lung cancer; toxicity

Indexed keywords

ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX;

ABDOMINAL PAIN; ACNE; ADD ON THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CONJUNCTIVITIS; COUGHING; DIARRHEA; DIET THERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSGEUSIA; DYSPNEA; EYE DISEASE; EYE IRRITATION; FATIGUE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INFECTION; INFESTATION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KERATITIS; KERATOCONJUNCTIVITIS SICCA; LUNG EMBOLISM; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; MEDIASTINUM DISEASE; MONOTHERAPY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL REHYDRATION THERAPY; PARONYCHIA; PNEUMONIA; PRURITUS; PUSTULE; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SOFT TISSUE DISEASE; SOLID TUMOR; STOMATITIS; THORAX DISEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 79961070410     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.74     Document Type: Article

References (57)

1. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958-2970 (2001). (Pubitemid 32963812)
2. Herbst RS. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59, 21-26 (2004). (Pubitemid 38610223)
3. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565 (2000). (Pubitemid 32197693)
4. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 19, 32S-40S (2001). (Pubitemid 32880077)
5. Engebraaten O, Bjerkvig R, Pedersen PH et al. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumor biopsies in vitro. Int. J. Cancer 53, 209-214 (1993). (Pubitemid 23042867)
6. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositideregulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Ann. Rev. Biochem. 68, 965-1014 (1999). (Pubitemid 29449213)
7. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23, 2445-2459 (2005). (Pubitemid 47050835)
8. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter Phase III trial BMS099. J. Clin. Oncol. 28(6), 911-917 (2010).
9. Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 14, 1116-1130 (2009).
10. Fukuoka M, Yano S, Giaccone G et al. A multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (the IDEAL 1 trial).J. Clin. Oncol. 21, 2237-2246 (2003). (Pubitemid 46621858)
11. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003). (Pubitemid 37432975)
12. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer).Lancet 366, 1527-1537 (2005). (Pubitemid 41540110)
13. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 353 (2005).
14. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled Phase 3 study. Lancet Oncol. 11, 521-529 (2010).
15. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007). (Pubitemid 46972777)
16. Reck M, Van Zandwijk N, Gridelli C et al. Erlotinib in advanced non-small-cell lung cancer (NSCLC): efficacy and safety findings of the global Phase IV trust study. J. Thorac. Oncol. 5(10), 1616-1622 (2010).
17. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 364, 947-955 (2011).
18. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279 (2001). (Pubitemid 32591445)
19. Yamamoto N, Horiike A, Fujisaka Y et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors cancer. Chemother. Pharmacol. 61, 489-496 (2008). (Pubitemid 350275984)
20. Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22, 3238-3234 (2004).
21. Miller VA, Riely GJ, Zakowski MF et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J. Clin. Oncol. 26(9), 1472-1478 (2008).
22. Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapynaive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol. 25(7), 760-766 (2007). (Pubitemid 350002874)
23. Kubota K, Nishiwaki Y, Tamura T et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a Phase II study. J. Thorac. Oncol. 3, 1439-1445 (2008).
24. Takahashi T, Yamamoto N, Nukiwa T et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res. 30, 557-564 (2010).
25. Yoshioka H, Hotta K, Kiura K et al.; Okayama Lung Cancer Study Group. A Phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J. Thorac. Oncol. 5, 99-104 (2010).
26. Mok TS, Wu YL, Yu CJ et al. Randomized, placebo-controlled, Phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-smallcell lung cancer. J. Clin. Oncol. 27, 5080-5087 (2009).
27. Mok T, Park K, Au JS et al. Efficacy and safety of erlotinib in 1200 east/south-east asian patients with advanced non-small-cell lung cancer. J. Thorac. Oncol. 5(10), 1609-1615 (2010).
28. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Eng. J. Med. 361, 958-967 (2009).
29. Zhou C, Wu Y-l, Chen G et al. Preliminary results of randomized Phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL).J. Clin. Oncol. 28(Suppl. 15; Pt 1), 556s-7575s (2010).
30. Hotta K, Kiura K, Takigawa N et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J. Thorac. Oncol. 5, 179-184 (2010).
31. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. Oncol. 30, 23-31 (2003). (Pubitemid 36712856)
32. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation trial. J. Clin. Oncol. 25, 1545-1552 (2007). (Pubitemid 46733081)
33. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J. Clin. Oncol. 23, 5892-5899 (2005).
34. Yoneda KY, Shelton DK, Beckett LA, Gandara DR. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J. Thorac. Oncol. 2(6), 537-543 (2007). (Pubitemid 47171809)
35. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(11), 2544-2555 (2005).
36. Miller VA, O'Connor P, Soh C et al. A randomized, double-blind, placebocontrolled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).J. Clin. Oncol. 27(Suppl. 18; Pt 2), LBA8002 (2009).
37. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12, 610-621 (2007). (Pubitemid 350012125)
38. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 4, 107-119 (2009).
39. Lacouture ME, Maitland ML, Segaert S et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18, 509-522 (2010).
40. Thatcher N, Nicolson M, Groves RW et al. UK erlotinib skin toxicity management consensus group. expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK. Oncologist 14(8), 840-847 (2009).
41. Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinibinduced skin rash in patients with nonsmall- cell lung cancer: pathogenesis, clinical significance, and management. Clin. Lung Cancer 10(2), 106-111 (2009).
42. Gridelli C, Maione P, Amoroso D et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an experts panel meeting. Crit. Rev. Oncol. Hematol. 66, 155-162 (2008).
43. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva®) tablets. Oncologist 10, 461-466 (2005). (Pubitemid 41266326)
44. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitorassociated side effects in GIST. Cancer Treat. Rev. 37(1), 75-88 (2011).
45. Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs).Eur. J. Surg. Oncol. 34, 844-850. (2008).
46. Griffin JM, Amand MS, Demetri GD. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. Clin. J. Oncol. Nurs. 9, 161-169 (2005).
47. Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J. Natl Compr. Canc. Netw. 5(Suppl. 2), S1-S29 (2007).
48. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21, 1637-1647 (2003). (Pubitemid 46594119)
49. Pérez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/ EGFR inhibitor rash management forum. Oncologist 10, 345-356 (2005). (Pubitemid 40647253)
50. Scope A, Agero AL, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J. Clin. Oncol. 25, 5390-5396 (2007). (Pubitemid 350232214)
51. Hotta K, Kiura K, Tabata M et al. Interstitial lung disease in patients with non-small-cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J. 11, 417-424 (2005). (Pubitemid 41725734)
52. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004). (Pubitemid 38720929)
53. Hosokawa S, Toyooka S, Fujiwara Y. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer 66, 107-113 (2009).
54. Hotta K, Kiura K, Toyooka S et al. clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in japanese patients with non-small-cell lung cancer. J. Thorac. Oncol. 2, 632-637 (2007). (Pubitemid 47171785)
55. Suehisa H, Toyooka S, Hotta K et al. Mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J. Clin. Oncol. 25, 3952-3957 (2007). (Pubitemid 47477273)
56. Fujiwara Y, Kiura K, Toyooka S. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 52, 99-103 (2006). (Pubitemid 43340206)
57. Fukui T, Otani S, Hataishi R et al. Successful rechallenge with erlotinib in a patient with EGFR mutant lung adenocarcinoma who developed gefitinibrelated interstitial lung disease. Cancer Chemother. Pharmacol. 65, 803-806 (2010).